Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical Trial

Cameron R. Wolfe, Jonathan Cohen, Kathryn Mahoney, Anna Holmes, Natalia Betancourt, Deepali Gupta, Kazima Tosh, Kristin Narayan, Ed Campanaro, Chloe Katz, Anne-Marie Phelan, Ilker Yalcin, Mark Wingertzahn, Pamela Hawn, Pete Schmidt, Yong Li, Myra Popejoy, the CANOPY Study Group
doi: https://doi.org/10.1101/2024.11.11.24317127

Data Availability

As this trial is ongoing, data are not publicly available.

Back to top
Posted November 13, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical Trial
Cameron R. Wolfe, Jonathan Cohen, Kathryn Mahoney, Anna Holmes, Natalia Betancourt, Deepali Gupta, Kazima Tosh, Kristin Narayan, Ed Campanaro, Chloe Katz, Anne-Marie Phelan, Ilker Yalcin, Mark Wingertzahn, Pamela Hawn, Pete Schmidt, Yong Li, Myra Popejoy, the CANOPY Study Group
medRxiv 2024.11.11.24317127; doi: https://doi.org/10.1101/2024.11.11.24317127
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area